Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Aires thérapeutiques
  • Ressources
Campus
  • Aires thérapeutiques
  • Ressources
View Full Results

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

Efluelda® - Vaccin antigrippal saisonnier à haute dose

Explorer

Airway remodeling in asthma: Why targeting IL-4 and IL-13 matters

Explorer

Les maladies du voyageur - La rage

Explorer

Les maladies du voyageur - Hépatite A

Explorer

Les maladies du voyageur

Explorer

Les maladies du voyageur - Fièvre Jaune

Explorer

Les maladies du voyageur - Fièvre typhoïde

Explorer

Beyfortus® ▼(nirsevimab): effectiveness and public health impact in the real world

Explorer

Gaucher disease in children

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient activity of the enzyme acid β glucosidase.

Explorer

Real-World Evidence and Phase IV studies in CRSwNP

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.

Explorer

DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP

The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3

Explorer

Efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities

Explorer